Zhejiang AngLiKang Pharmaceutical CO.,LTD. (002940.SZ)
CNY 13.82
(-0.22%)
CNY 13.82
(-0.22%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 276.9 Million | 184.74 Million | 197.65 Million | 198.61 Million | 213.49 Million | 133.61 Million |
| Net Income | 183.06 Million | 131.98 Million | 141.32 Million | 181.3 Million | 126.45 Million | 121.66 Million |
| Depreciation & Amortization | 78.77 Million | 61.1 Million | 46.35 Million | 41.69 Million | 38.15 Million | 39.23 Million |
| Deferred income taxes | -529.83 Thousand | -242.88 Thousand | 2.15 Million | -5.61 Million | 2.99 Million | -18.03 Million |
| Stock-based compensation | - | 1.87 Million | - | - | - | - |
| Change in working capital | -21.84 Million | -24.04 Million | -5.42 Million | -35.7 Million | 31.64 Million | -19.21 Million |
| Other non-cash items | 36.91 Million | 14.06 Million | 15.39 Million | 11.32 Million | 17.24 Million | -8.07 Million |
| Investing Cash Flow | -170 Million | -521.31 Million | -232.8 Million | 20.66 Million | -228.79 Million | -69.09 Million |
| Investments in PPE | -124.94 Million | -68.82 Million | -87.31 Million | -90.96 Million | -75.58 Million | -68.17 Million |
| Acquisitions | -117.48 Million | 17.56 Million | 376.08 Thousand | 201.75 Thousand | 197.3 Thousand | 68.21 Million |
| Investment purchases | -1.5 Million | -487.86 Million | -95 Million | -42.26 Million | -6.61 Million | -2.45 Million |
| Sales/Maturities of investments | 45.42 Million | 3.35 Million | 3.76 Million | 3.68 Million | 3.15 Million | 1.48 Million |
| Other Investing Activities | 28.49 Million | 14.45 Million | -54.62 Million | 150 Million | -149.95 Million | -68.17 Million |
| Financing Cash Flow | 15.65 Million | 376.61 Million | -123.59 Million | 177.4 Million | -97.33 Million | 397.7 Million |
| Debt repayment | -163.14 Million | -27.98 Million | -12 Million | -10 Million | -15 Million | -80 Million |
| Dividends payments | -41.73 Million | -28.16 Million | -46.94 Million | -90 Million | -67.5 Million | -1.92 Million |
| Common Stock Repurchased | -20.12 Million | -63.32 Million | -63.33 Million | - | - | - |
| Common Stock Issuance | - | 63.32 Million | 63.33 Million | - | - | 464.63 Million |
| Other Financing Activities | -56.47 Million | 438.76 Million | -64.53 Million | 277.47 Million | -14.8 Million | 479.63 Million |
| Accounts receivables | 86.63 Million | -47.82 Million | -39.99 Million | -51.43 Million | 109.61 Million | -39.98 Million |
| Accounts payables | -84.13 Million | 21.96 Million | 57.56 Million | 173.55 Million | -111.07 Million | 59.96 Million |
| Inventory | -23.81 Million | 2.06 Million | -25.15 Million | -152.2 Million | 30.1 Million | -21.16 Million |
| Other working capital | 1.97 Million | -242.88 Thousand | 2.15 Million | -5.61 Million | 2.99 Million | 1.94 Million |
| Cash at beginning of period | 728.89 Million | 687.57 Million | 846.9 Million | 450.56 Million | 563.14 Million | 100.45 Million |
| Cash at end of period | 852.61 Million | 728.89 Million | 687.57 Million | 846.9 Million | 450.56 Million | 563.14 Million |
| Capital Expenditure | -124.94 Million | -68.82 Million | -87.31 Million | -90.96 Million | -75.58 Million | -68.17 Million |
| Effect of forex changes on cash | 1.16 Million | 1.27 Million | -578.37 Thousand | -334.26 Thousand | 58.92 Thousand | 461.4 Thousand |
| Net cash flow / Change in cash | 123.71 Million | 41.31 Million | -159.32 Million | 396.34 Million | -112.58 Million | 462.68 Million |
| Free Cash Flow | 151.96 Million | 115.92 Million | 110.33 Million | 107.64 Million | 137.9 Million | 65.44 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -18.16 Million | 39.87 Million | 28.21 Million | 183.06 Million | 28.57 Million | 5.56 Million |
| Depreciation & Amortization | - | 23.12 Million | 23.12 Million | 78.77 Million | 24.2 Million | 24.2 Million |
| Deferred income taxes | - | - | - | -529.83 Thousand | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | -41.68 Million | - | -21.84 Million | - | - |
| Other non-cash items | 85.38 Million | 18.14 Million | 133.11 Million | 36.91 Million | -46.09 Million | 104.46 Million |
| Investing Cash Flow | -266 Million | -84.83 Million | -55.68 Million | -170 Million | -1.57 Million | 14.27 Million |
| Investments in PPE | -23.04 Million | -13.94 Million | -48.29 Million | -124.94 Million | -6.69 Million | -57.43 Million |
| Acquisitions | 432.03 Thousand | 109.1 Thousand | 35.55 Thousand | -117.48 Million | 6.97 Million | -6.97 Million |
| Investment purchases | 235.81 Million | -306 Million | -2.5 Million | -1.5 Million | 462.24 Thousand | - |
| Sales/Maturities of investments | -230 Million | 230 Million | 71.55 Thousand | 45.42 Million | 40.1 Million | 4.63 Million |
| Other Investing Activities | -243.38 Million | 5 Million | -5 Million | 28.49 Million | -42.43 Million | 74.04 Million |
| Financing Cash Flow | -45.77 Million | -57.5 Million | 11.97 Million | 15.65 Million | -88.2 Million | 164.26 Million |
| Debt repayment | -42 Million | -10.72 Million | -30.5 Million | -163.14 Million | -57.21 Million | -57 Million |
| Dividends payments | - | -46.88 Million | -4.45 Million | -41.73 Million | -41.73 Million | -5.21 Million |
| Common Stock Repurchased | 13.97 Million | -13.97 Million | - | -20.12 Million | -20.12 Million | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -59.74 Million | -32.81 Million | -14.07 Million | -56.47 Million | -27.21 Million | 226.47 Million |
| Accounts receivables | - | 3.15 Million | - | 86.63 Million | - | - |
| Accounts payables | - | - | - | -84.13 Million | - | - |
| Inventory | - | -49.02 Million | - | -23.81 Million | - | - |
| Other working capital | - | 4.18 Million | - | 1.97 Million | - | - |
| Cash at beginning of period | 879.24 Million | 981.56 Million | 852.61 Million | 728.89 Million | 982.56 Million | 693.37 Million |
| Cash at end of period | 635.61 Million | 879.24 Million | 971.92 Million | 852.61 Million | 852.61 Million | 982.56 Million |
| Capital Expenditure | -23.04 Million | -13.94 Million | -48.29 Million | -124.94 Million | -6.69 Million | -57.43 Million |
| Effect of forex changes on cash | - | 3.17 Million | 1.76 Million | 1.16 Million | -851.99 Thousand | 626.02 Thousand |
| Net cash flow / Change in cash | -243.62 Million | -102.32 Million | 119.31 Million | 123.71 Million | -129.95 Million | 289.19 Million |
| Free Cash Flow | 44.17 Million | 20.95 Million | 113.03 Million | 151.96 Million | -46.01 Million | 52.6 Million |
000659
5345
7731
FBVI
300313
JRVR